May 8, 2020
Ocular Therapeutix CEO: outlook continues to brighten
First Quarter DEXTENZA® Net Product Revenue of $2.1 million, a 31% Sequential Increase Compared with Fourth Quarter of 2019
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Ocular Therapeutix
May 20, 2019
Ocular Therapeutix’s glaucoma treatment fails to meet primary endpoint in P3 trial, for gets statistically significant reduction of intraocular pressure versus placebo
OTX-TP failed to meet primary endpoint but achieved statisticallysignificant reduction of intraocular pressure versus placebo at eight ofthe nine pre-specified time points
May 10, 2019
Ocular Therapeutix posts net loss of $17.1 million in the first quarter of 2019
Ocular Therapeutix posts net loss of $17.1 million in the first quarter of 2019
April 2, 2019
Ocular Therapeutix™ Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
PDUFA Target Action Date Set for November 10, 2019 BEDFORD, Mass.–(BUSINESS WIRE)—-Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused…